Ascentage aims to raise $149 mln via US IPO Plans to offer 7.3 mln American depositary shares at $20.34 each Company's shares already listed in Hong Kong Jan 21 (Reuters) - Ascentage Pharma (6855 ...

Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight loss versus the anticipated 25%. The stock is down 42% from its June ...

In this case, the culprit was CagriSema, the company’s potential next-generation weight-loss treatment. Novo had set a target for patients to lose 25% of their body weight on average over 68 weeks.

Well, it was the age-old bane of pharma firms, namely disappointing late-stage clinical trial results. In this case, the culprit was CagriSema, the company’s potential next-generation weight-loss ...

The most prescribed GLP-1 drugs include Ozempic, Wegovy, Mounjaro, CagriSema and Rybelsus. Salty snacks are seeing a slight decline but weren’t on the list of top products experiencing spending ...

I mean stuff. Matter. Material. Substances. Particularly in opening title sequences of TV series, where all manner of effluvia flows, wends and re-forms, through the magic of C.G.I., into shapes ...

Expectations have gotten so high that Novo Nordisk’s stock actually dropped when it announced that their drug candidate CagriSema (a mix of semaglutide with the experimental drug cagrilintide ...

CagriSema (cagrilintide + semaglutide) developed by Novo Nordisk|obesity and type 2 diabetes mellitus. CagriSema, combining cagrilintide, a long-acting amylin analog, with semaglutide, promises ...

Per the data readout from the phase III REDEFINE 1 study, a weight loss of 22.7% was observed in patients treated with CagriSema, which missed NVO’s guidance of 25% weight loss at week 68 ...